First time I see this. For BCG-Unresponsive, Merck obtained the Accelerated Approval. In 0.5 month! BLA 125514 Supplement 79 4 KEYTRUDA PEMBROLIZUMAB MERCK SHARP & DOHME 4/14/2020 4/28/2020 0.5 PROVIDES FOR AN ALTERNATE DOSE/SCHEDULE OF 400MG EVERY 6 WEEKS FOR ADULT PATIENTS WITH BCG-UNRESPONSIVE, HIGH RISK, NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WITH CARCINOMA IN-SITU (CIS) WITH
...more